• 1
    Chobanian AV, Bakris GL, Black HR. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061262.
  • 2
    Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012;14(1) Doi: 10.1111/j.1751-7176.2011.00556.
  • 3
    Silverstein RL, Ram CV. Resistant hypertension. Prim Care. 2008;35:501513.
  • 4
    Ram CV. Review of resistant hypertension. Curr Hypertens Rep. 2006;8:398402.
  • 5
    Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:10461058.
  • 6
    Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:19401946.
  • 7
    Voskuil M, Verloop WL, Blankestijn PJ, et al. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J. 2011;19:319323.
  • 8
    Bisognano JD, Kaufman CL, Bach DS, et al. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol. 2011;26:57.
  • 9
    Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patient with resistant hypertension results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol. 2011;58:765773.
  • 10
    Ram CV. Could baroreceptor activation therapy be the future for treating hypertension and other chronic cardiovascular conditions? J Clin Hypertens (Greenwich). 2010;12:288291.